WO2007149480A3 - Reduced isoalpha acid based protein kinase modulation cancer treatment - Google Patents
Reduced isoalpha acid based protein kinase modulation cancer treatment Download PDFInfo
- Publication number
- WO2007149480A3 WO2007149480A3 PCT/US2007/014372 US2007014372W WO2007149480A3 WO 2007149480 A3 WO2007149480 A3 WO 2007149480A3 US 2007014372 W US2007014372 W US 2007014372W WO 2007149480 A3 WO2007149480 A3 WO 2007149480A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein kinase
- cancer treatment
- acid based
- based protein
- kinase modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002654964A CA2654964A1 (en) | 2006-06-20 | 2007-06-20 | Reduced isoalpha acid based protein kinase modulation cancer treatment |
JP2009516557A JP2009541324A (en) | 2006-06-20 | 2007-06-20 | Protein kinase-regulated cancer therapy based on reduced isoalpha acid |
AU2007261399A AU2007261399A1 (en) | 2006-06-20 | 2007-06-20 | Reduced isoalpha acid based protein kinase modulation cancer treatment |
EP07809708A EP2046355A4 (en) | 2006-06-20 | 2007-06-20 | Reduced isoalpha acid based protein kinase modulation cancer treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81506406P | 2006-06-20 | 2006-06-20 | |
US60/815,064 | 2006-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007149480A2 WO2007149480A2 (en) | 2007-12-27 |
WO2007149480A3 true WO2007149480A3 (en) | 2008-07-10 |
Family
ID=38833737
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014380 WO2007149485A1 (en) | 2006-06-20 | 2007-06-20 | Acacia based protein kinase modulation cancer treatment |
PCT/US2007/014412 WO2007149503A2 (en) | 2006-06-20 | 2007-06-20 | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014372 WO2007149480A2 (en) | 2006-06-20 | 2007-06-20 | Reduced isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014413 WO2007149504A2 (en) | 2006-06-20 | 2007-06-20 | Isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014374 WO2007149482A2 (en) | 2006-06-20 | 2007-06-20 | Xanthohumol based protein kinase modulation cancer treatment |
PCT/US2007/014450 WO2007149523A2 (en) | 2006-06-20 | 2007-06-20 | Hexahydro-isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014373 WO2007149481A2 (en) | 2006-06-20 | 2007-06-20 | Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014414 WO2007149505A2 (en) | 2006-06-20 | 2007-06-20 | Beta acid based protein kinase modulation cancer treatment |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014380 WO2007149485A1 (en) | 2006-06-20 | 2007-06-20 | Acacia based protein kinase modulation cancer treatment |
PCT/US2007/014412 WO2007149503A2 (en) | 2006-06-20 | 2007-06-20 | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014413 WO2007149504A2 (en) | 2006-06-20 | 2007-06-20 | Isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014374 WO2007149482A2 (en) | 2006-06-20 | 2007-06-20 | Xanthohumol based protein kinase modulation cancer treatment |
PCT/US2007/014450 WO2007149523A2 (en) | 2006-06-20 | 2007-06-20 | Hexahydro-isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014373 WO2007149481A2 (en) | 2006-06-20 | 2007-06-20 | Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
PCT/US2007/014414 WO2007149505A2 (en) | 2006-06-20 | 2007-06-20 | Beta acid based protein kinase modulation cancer treatment |
Country Status (9)
Country | Link |
---|---|
US (6) | US20080031894A1 (en) |
EP (4) | EP2043622A4 (en) |
JP (4) | JP2009541326A (en) |
KR (4) | KR20090026191A (en) |
CN (4) | CN101573128A (en) |
AU (4) | AU2007261399A1 (en) |
CA (4) | CA2655047A1 (en) |
TW (8) | TW200819121A (en) |
WO (8) | WO2007149485A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7736677B2 (en) * | 2001-06-20 | 2010-06-15 | Metaproteomics, Llc | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
CN101573128A (en) * | 2006-06-20 | 2009-11-04 | 麦特普罗泰欧米克斯有限公司 | Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
US20080051466A1 (en) * | 2006-06-20 | 2008-02-28 | Metaproteomics, Llc | Isoalpha acid based protein kinase modulation cancer treatment |
EP2052728B1 (en) * | 2006-08-10 | 2018-06-13 | mimozax Co., Ltd. | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia |
KR101398737B1 (en) * | 2006-08-10 | 2014-05-27 | 가부시키가이샤 미모잭스 | Composition for preventing and/or treating tumor containing component originating in the bark of tree belonging to the genus acacia |
US20100160450A1 (en) * | 2007-01-31 | 2010-06-24 | Eric Kuhrts | Methods of reducing 15-f2t-isop levels in mammals |
MX2010006425A (en) * | 2007-12-10 | 2010-08-31 | Metaproteomics Llc | Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith. |
US20110092591A1 (en) * | 2008-02-06 | 2011-04-21 | Noscira S.A. | Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
JP2010043064A (en) * | 2008-07-16 | 2010-02-25 | Sapporo Breweries Ltd | Fat cell differentiation inhibitor |
WO2010056406A1 (en) | 2008-11-12 | 2010-05-20 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of erbb4 as a prognostic and therapeutic marker for melanoma |
AU2010300531A1 (en) | 2009-09-30 | 2012-05-24 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
CN102724994A (en) * | 2010-01-11 | 2012-10-10 | 希尔洛有限公司 | Method for treatment of inflammatory disease and disorder |
WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
EP2720693B8 (en) | 2011-06-17 | 2017-05-17 | Ludwig Aigner | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders |
US9499856B2 (en) | 2012-04-02 | 2016-11-22 | The Board Institute, Inc. | DDR2 mutations in squamous cell lung cancer |
CN104399044A (en) * | 2014-12-01 | 2015-03-11 | 郑州后羿制药有限公司 | Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation |
CN105168946A (en) * | 2015-10-22 | 2015-12-23 | 陈远征 | Traditional Chinese medicine composition for treating diabetes mellitus and application thereof |
CN105126040A (en) * | 2015-10-23 | 2015-12-09 | 戚炎月 | Medicine compound treating ovarian cysts and preparation method thereof |
US10918650B2 (en) * | 2016-06-02 | 2021-02-16 | University Of South Florida | Method of treating melanoma using an inhibitor of an atypical protein kinase C |
CN106153920B (en) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | A kind of screening lung cancer kit |
CN107115328B (en) * | 2017-05-24 | 2019-08-30 | 中美(河南)荷美尔肿瘤研究院 | Application of the xanthohumol in terms of preparing protein kinase B inhibitor |
CN108535480B (en) * | 2018-03-05 | 2020-03-06 | 南通大学附属医院 | Application of EphA8 gene in preparation of anti-breast cancer drug and diagnostic kit thereof |
CN108586226B (en) * | 2018-05-31 | 2021-06-18 | 温州医科大学 | 3-methyl-3-butene-2-alcohol chalcone compound and synthesis and application thereof |
CN110833550B (en) * | 2018-08-15 | 2023-03-24 | 广西梧州制药(集团)股份有限公司 | Application of pyrazolopyrimidine derivative in treatment of liver injury caused by acute pancreatitis |
CN114921546B (en) * | 2022-05-13 | 2023-02-21 | 核工业总医院 | Application of circHIPK2 as breast cancer biomarker |
CN116102416A (en) * | 2023-02-21 | 2023-05-12 | 蚌埠医学院 | Bavachin derivatives, preparation method thereof and application thereof in preparation of anticancer drugs |
CN116196301B (en) * | 2023-04-27 | 2023-07-28 | 北京中医药大学 | Chalcone alpha-glucosidase inhibitor and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391346B1 (en) * | 2001-04-05 | 2002-05-21 | Thomas Newmark | Anti-inflammatory, sleep-promoting herbal composition and method of use |
US20040151792A1 (en) * | 2001-06-20 | 2004-08-05 | Tripp Matthew L. | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3933919A (en) * | 1964-12-15 | 1976-01-20 | Geoffrey Wilkinson | Hydroformylation of mono-α-olefins and mono-α-acetylenes |
US3451921A (en) * | 1965-01-25 | 1969-06-24 | Union Carbide Corp | Coke production |
GB1145240A (en) * | 1965-03-01 | 1969-03-12 | Kalamazoo Spice Extract Co | Hop flavours for malt beverages and the like |
US3451821A (en) * | 1965-03-01 | 1969-06-24 | Kalamazoo Spice Extract Co | Increasing the utilization of hops and improving flavor control of malt beverages and the like |
US3536495A (en) * | 1968-03-13 | 1970-10-27 | Miller Brewing | Ammonia complexes of hop alpha acids and modified alpha acids |
US3720517A (en) * | 1970-12-21 | 1973-03-13 | Hamm T Brewing Co | Preparation of a fermented malt champagne |
US3932603A (en) * | 1971-05-28 | 1976-01-13 | General Foods Corporation | Oral preparations for reducing the incidence of dental caries |
US3965188A (en) * | 1972-01-10 | 1976-06-22 | Miller Brewing Company | Hop extract process and product |
CH617326A5 (en) * | 1975-12-04 | 1980-05-30 | Siegfried Ag | |
JPS52145509A (en) * | 1976-05-27 | 1977-12-03 | Tokutarou Matsui | Antitumor agent |
US4170638A (en) * | 1976-11-05 | 1979-10-09 | S. S. Steiner, Inc. | Method for producing a deodorant |
US4148873A (en) * | 1976-11-05 | 1979-04-10 | S. S. Steiner, Inc. | Method for treating the skin with extracts of hops |
US4123561A (en) * | 1977-02-01 | 1978-10-31 | S.S. Steiner, Inc. | Method for processing hops for brewing |
US4401684A (en) * | 1981-10-01 | 1983-08-30 | Australian Hop Marketers Pty. Ltd. | Preservation of hops utilizing ascorbic acid |
US4389421A (en) * | 1981-10-30 | 1983-06-21 | Busch Industrial Products Corporation | Method for controlling light stability in malt beverages and product thereof |
US4473551A (en) * | 1982-08-23 | 1984-09-25 | Faxon Pharmaceuticals, Inc. | Anti-inflammatory composition |
US4644084A (en) * | 1984-01-25 | 1987-02-17 | Miller Brewing Company | Preparation of tetrahydroisohumulones |
US4590296A (en) * | 1984-01-25 | 1986-05-20 | Miller Brewing Company | Process for separation of beta-acids from extract containing alpha-acids and beta-acids |
DE3513169A1 (en) * | 1985-04-12 | 1986-10-16 | Hopstabil Hopfenverarbeitungs-Gesellschaft mbH, 8069 Wolnzach | METHOD FOR PRODUCING ISOHUMULONES |
US4767640A (en) * | 1985-10-29 | 1988-08-30 | Miller Brewing Company | Light stable hop extracts and method of preparation |
US4692280A (en) * | 1986-12-01 | 1987-09-08 | The United States Of America As Represented By The Secretary Of Commerce | Purification of fish oils |
US5041300A (en) * | 1987-04-03 | 1991-08-20 | Kalamazoo Holdings, Inc. | Hop flavor which is odor forming impurity free |
DE3712986A1 (en) * | 1987-04-16 | 1988-10-27 | Marbert Gmbh | MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT |
US4857554A (en) * | 1987-08-17 | 1989-08-15 | Georgios Kallimanis | Method for the treatment of psoriasis |
US5082975A (en) * | 1988-08-15 | 1992-01-21 | Kalamazoo Holdings, Inc. | Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication |
US5013571A (en) * | 1990-01-31 | 1991-05-07 | Pfizer Inc. | Methods for making tetrahydroisoalpha and hexahydroisoalpha acids |
DE59010282D1 (en) * | 1990-09-10 | 1996-05-15 | Fromm Mayer Bass Ltd | A process for isomerizing humulon in a carbon dioxide hop extract and a process for obtaining isohumulone therefrom |
TW199905B (en) * | 1992-02-03 | 1993-02-11 | J E Siebel Sons Company Inc | Method and composition for enhancing foam properties of fermented malt beverages |
AU4715093A (en) * | 1992-07-29 | 1994-03-03 | Matforsk, Norwegian Food Research Institute | Composition comprising fertilized shell eggs |
US5286506A (en) * | 1992-10-29 | 1994-02-15 | Bio-Technical Resources | Inhibition of food pathogens by hop acids |
US5296637A (en) * | 1992-12-31 | 1994-03-22 | Kalamazoo Holdings, Inc. | Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization |
US5866162A (en) * | 1993-08-10 | 1999-02-02 | Smithkline Beecham P.L.C. | Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple |
EP0992581B2 (en) * | 1993-11-04 | 2011-05-25 | Innogenetics N.V. | Immunodominant human T-cell epitopes of hepatitis C virus |
JP2677762B2 (en) * | 1994-04-08 | 1997-11-17 | 株式会社神戸製鋼所 | Oil-cooled compressor |
DE69507185T2 (en) * | 1994-04-12 | 1999-09-09 | Hoechst Marion Roussel Inc | Medicines used to treat osteoporosis |
IN184685B (en) * | 1996-02-14 | 2000-09-23 | Nat Inst Immunology | |
US5827895A (en) * | 1996-02-27 | 1998-10-27 | Regents Of The University Of Minnesota | Hexahydrolupulones useful as anticancer agents |
US6020019A (en) * | 1996-03-26 | 2000-02-01 | Miller Brewing Company | Hydrogenation of hop soft resins using CO2 |
US6589994B1 (en) * | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
US5968539A (en) * | 1997-06-04 | 1999-10-19 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria |
US6224871B1 (en) * | 1998-03-11 | 2001-05-01 | Reliv International, Inc. | Dietary supplement for nutritionally promoting healthy joint function |
US5919813C1 (en) * | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
ES2147538B1 (en) * | 1999-01-29 | 2001-04-01 | Revlon Consumer Prod Corp | A CAPILLARY LOTION WITH IMPROVED PROPERTIES IN ITS HAIR PROTECTIVE AND PREVENTIVE ACTION OF HIS FALL, AND REDUCTION OF THE EXTERNAL EFFECTS OF ANDROGENETIC ALOPECIA AND WITH THAT OF THE HAIR FALL. |
US6801860B1 (en) * | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
US6462029B1 (en) * | 1999-02-23 | 2002-10-08 | Econugenics | Compositions and methods for treating mammals with modified alginates and modified pectins |
US6383527B1 (en) * | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US6129907A (en) * | 1999-08-04 | 2000-10-10 | Colgate Palmolive Company | Stable hydrogenated lupulone antibacterial oral compositions |
AU7596100A (en) * | 1999-09-21 | 2001-04-24 | Rutgers, The State University | Resveratrol analogs for prevention of disease |
US6264995B1 (en) * | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
US6200594B1 (en) * | 1999-12-29 | 2001-03-13 | Vital Dynamics, Inc. | Breast-enhancing, herbal compositions and methods of using same |
US6953593B2 (en) * | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
US6583322B1 (en) * | 2000-02-25 | 2003-06-24 | Kalamazoo Holdings, Inc. | Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same |
US20020086070A1 (en) * | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
EP1295587A1 (en) * | 2000-03-31 | 2003-03-26 | The Nisshin OilliO, Ltd. | External preparation for the skin and beautifying agents |
US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
US20020076452A1 (en) * | 2000-08-01 | 2002-06-20 | Ashni Naturaceuticals, Inc. | Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
US6908630B2 (en) * | 2000-08-01 | 2005-06-21 | Metaproteomics, Llc | Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2 |
FR2815227B1 (en) * | 2000-10-17 | 2003-04-11 | Schwartz Laboratoires Robert | ANTI-STRESS COMPOSITION FOR PRIMARY INCORPORATION IN NUTRITIONAL VEHICLES |
US6790459B1 (en) * | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
US7078062B2 (en) * | 2001-01-17 | 2006-07-18 | S.S. Steiner, Inc. | Hop-based udder and teat dips and washes |
US20020187239A1 (en) * | 2001-02-06 | 2002-12-12 | Dusan Miljkovic | Nutraceuticals and methods of obtaining nutraceuticals from tropical crops |
US20030035851A1 (en) * | 2001-02-08 | 2003-02-20 | Sophie Chen | Anti-cancer agents and method of use thereof |
US20030003212A1 (en) * | 2001-06-13 | 2003-01-02 | Givaudan Sa | Taste modifiers |
US8142819B2 (en) * | 2002-10-21 | 2012-03-27 | Metaproteomics, Llc | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7718198B2 (en) * | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
US7736677B2 (en) * | 2001-06-20 | 2010-06-15 | Metaproteomics, Llc | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
US20040115290A1 (en) * | 2001-06-20 | 2004-06-17 | Tripp Matthew L. | Modulation of inflammation by hops fractions and derivatives |
US7901713B2 (en) * | 2001-06-20 | 2011-03-08 | Metaproteomics, Llc | Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops |
US7901714B2 (en) * | 2001-06-20 | 2011-03-08 | Metaproteomics, Llp | Treatment modalities for autoimmune diseases |
US8168234B2 (en) * | 2001-06-20 | 2012-05-01 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7205151B2 (en) * | 2001-06-20 | 2007-04-17 | Metaproteomics, Llc | Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
US20030082511A1 (en) * | 2001-09-25 | 2003-05-01 | Brown Steven J. | Identification of modulatory molecules using inducible promoters |
MXPA04003734A (en) * | 2001-10-26 | 2005-06-20 | Metaproteomics Llc | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2. |
US7279185B2 (en) * | 2001-10-26 | 2007-10-09 | Metaproteonics, Llc | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
KR100993113B1 (en) * | 2002-02-14 | 2010-11-08 | 기린 홀딩스 가부시키가이샤 | Compositions and foods for improving lipid metabolism |
US7108868B2 (en) * | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
ATE361746T1 (en) * | 2002-03-06 | 2007-06-15 | Medical Res And Education Trus | BOTANICAL EXTRACT WITH ANTI-CANCER ACTIVITY CONTAINING ISOLIQUIRITIGENIN |
WO2004037180A2 (en) * | 2002-10-21 | 2004-05-06 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7144590B2 (en) * | 2003-01-09 | 2006-12-05 | Lipoprotein Technologies, Inc. | Bioactive compositions derived from humulus lupulus |
MXPA05013061A (en) * | 2003-06-05 | 2006-03-02 | Warner Lambert Co | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents. |
GB0317020D0 (en) * | 2003-07-21 | 2003-08-27 | Sahajanand Biotech Private Ltd | Herbo-mineral formulation for refractory leukemias and lymphomas |
US20050192356A1 (en) * | 2004-02-27 | 2005-09-01 | Babish John G. | Synergistic anti-inflammatory pharmaceutical compositions and methods of use |
US7914831B2 (en) * | 2004-02-27 | 2011-03-29 | Metaproteomics, Llc | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
US20090274778A1 (en) * | 2004-11-13 | 2009-11-05 | Babish John G | Compositions Exhibiting Inhibition Of Cyclooxygenase-2 |
MX2008001903A (en) * | 2005-08-09 | 2008-04-16 | Metaproteomics Llc | Protein kinase modulation by hops and acacia products. |
US20070065456A1 (en) * | 2005-09-20 | 2007-03-22 | Woods Cindy J | Nutritional supplements |
US20070154576A1 (en) * | 2005-12-09 | 2007-07-05 | Tripp Matthew L | Protein kinase modulation by hops and Acacia products |
CN101573128A (en) * | 2006-06-20 | 2009-11-04 | 麦特普罗泰欧米克斯有限公司 | Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
US8062898B2 (en) * | 2006-10-20 | 2011-11-22 | The Board Of Trustees Of The University Of Illinois | Selection and rational development of solvent systems in counter-current chromatograph |
FR2910325B1 (en) * | 2006-12-22 | 2010-03-19 | Kronenbourg Brasseries | USE OF LUPULONES FOR THE PREVENTION AND THERAPY OF COLORECTAL CANCER. |
-
2007
- 2007-06-20 CN CNA200780030592XA patent/CN101573128A/en active Pending
- 2007-06-20 US US11/820,755 patent/US20080031894A1/en not_active Abandoned
- 2007-06-20 WO PCT/US2007/014380 patent/WO2007149485A1/en active Application Filing
- 2007-06-20 TW TW096122225A patent/TW200819121A/en unknown
- 2007-06-20 US US11/820,608 patent/US20080033057A1/en not_active Abandoned
- 2007-06-20 JP JP2009516562A patent/JP2009541326A/en not_active Withdrawn
- 2007-06-20 TW TW096122216A patent/TW200816982A/en unknown
- 2007-06-20 WO PCT/US2007/014412 patent/WO2007149503A2/en active Application Filing
- 2007-06-20 AU AU2007261399A patent/AU2007261399A1/en not_active Abandoned
- 2007-06-20 US US11/820,747 patent/US20080033056A1/en not_active Abandoned
- 2007-06-20 CN CNA2007800306119A patent/CN101505743A/en active Pending
- 2007-06-20 EP EP07845228A patent/EP2043622A4/en not_active Withdrawn
- 2007-06-20 US US11/820,621 patent/US20080031893A1/en not_active Abandoned
- 2007-06-20 KR KR1020097001251A patent/KR20090026191A/en not_active Application Discontinuation
- 2007-06-20 CN CNA2007800305281A patent/CN101505770A/en active Pending
- 2007-06-20 US US11/820,653 patent/US20080026088A1/en not_active Abandoned
- 2007-06-20 WO PCT/US2007/014372 patent/WO2007149480A2/en active Application Filing
- 2007-06-20 TW TW096122231A patent/TW200817027A/en unknown
- 2007-06-20 EP EP07809709A patent/EP2046353A4/en not_active Withdrawn
- 2007-06-20 WO PCT/US2007/014413 patent/WO2007149504A2/en active Application Filing
- 2007-06-20 WO PCT/US2007/014374 patent/WO2007149482A2/en active Application Filing
- 2007-06-20 KR KR1020097001246A patent/KR20090023719A/en not_active Application Discontinuation
- 2007-06-20 TW TW096122223A patent/TW200816980A/en unknown
- 2007-06-20 KR KR1020097001249A patent/KR20090023721A/en not_active Application Discontinuation
- 2007-06-20 JP JP2009516557A patent/JP2009541324A/en not_active Withdrawn
- 2007-06-20 AU AU2007261400A patent/AU2007261400A1/en not_active Abandoned
- 2007-06-20 EP EP07796314A patent/EP2043621A4/en not_active Ceased
- 2007-06-20 CA CA002655047A patent/CA2655047A1/en not_active Abandoned
- 2007-06-20 CN CNA2007800305722A patent/CN101505742A/en active Pending
- 2007-06-20 WO PCT/US2007/014450 patent/WO2007149523A2/en active Application Filing
- 2007-06-20 WO PCT/US2007/014373 patent/WO2007149481A2/en active Application Filing
- 2007-06-20 WO PCT/US2007/014414 patent/WO2007149505A2/en active Application Filing
- 2007-06-20 CA CA002655059A patent/CA2655059A1/en not_active Abandoned
- 2007-06-20 AU AU2007261338A patent/AU2007261338A1/en not_active Abandoned
- 2007-06-20 CA CA002655043A patent/CA2655043A1/en not_active Abandoned
- 2007-06-20 KR KR1020097001254A patent/KR20090023722A/en not_active Application Discontinuation
- 2007-06-20 EP EP07809708A patent/EP2046355A4/en not_active Withdrawn
- 2007-06-20 JP JP2009516569A patent/JP2009541329A/en not_active Withdrawn
- 2007-06-20 TW TW096122220A patent/TW200817023A/en unknown
- 2007-06-20 AU AU2007261356A patent/AU2007261356A1/en not_active Abandoned
- 2007-06-20 TW TW096122224A patent/TW200819120A/en unknown
- 2007-06-20 TW TW096122217A patent/TW200817022A/en unknown
- 2007-06-20 JP JP2009516558A patent/JP2009541325A/en not_active Withdrawn
- 2007-06-20 US US11/820,600 patent/US20080031982A1/en not_active Abandoned
- 2007-06-20 TW TW096122227A patent/TW200817026A/en unknown
- 2007-06-20 CA CA002654964A patent/CA2654964A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391346B1 (en) * | 2001-04-05 | 2002-05-21 | Thomas Newmark | Anti-inflammatory, sleep-promoting herbal composition and method of use |
US20040151792A1 (en) * | 2001-06-20 | 2004-08-05 | Tripp Matthew L. | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
Non-Patent Citations (1)
Title |
---|
KOSTICH M. ET AL: "Human members of the eukaryotic protein kinase family", GENOME BIOLOGY, vol. 3, no. 9, 2002, pages 0043.1 - 0043.12, XP021021160 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007149480A3 (en) | Reduced isoalpha acid based protein kinase modulation cancer treatment | |
WO2006127900A3 (en) | Tl1a in the treatment of disease | |
WO2006102283A3 (en) | Beta-lactamylalkanoic acids for treating premenstrual disorders | |
WO2009009173A3 (en) | Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases | |
WO2007061874A3 (en) | Methods and compositions for use in treating cancer | |
WO2004050707A3 (en) | Tumor-specific recognition molecules | |
WO2007024705A3 (en) | Method of treating depression using a tnf-alpha antibody | |
WO2006004833A3 (en) | Pyrrolotriazine kinase inhibitors | |
WO2007059008A3 (en) | N-substituted indenoisoquinolines and syntheses thereof | |
WO2006128455A3 (en) | Compounds modifying apoptosis | |
AU2005316238B2 (en) | Cancer treatment method | |
WO2007146335A3 (en) | Compounds and compositions for treatment of cancer | |
WO2006034035A3 (en) | Treatment of ischemia | |
WO2006078422A3 (en) | Methods for modulating tumor growth and metastasis | |
WO2005009434A3 (en) | Compounds and methods for inducing apoptosis in cancer cells | |
WO2007076174A3 (en) | Methods, systems, and apparatus for multi-domain markers | |
WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators | |
WO2005074645A3 (en) | Methods and compositions for modulating angiogenesis | |
WO2006050826A3 (en) | Treatment of mastitis with enrofloxacin | |
WO2006105502A3 (en) | Catheter | |
WO2007033374A3 (en) | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor | |
WO2007076320A8 (en) | Compounds | |
WO2006052826A3 (en) | Methods for preparing cells and viruses | |
WO2005034840A8 (en) | Identification of kinase inhibitors | |
WO2007059323A3 (en) | Certain chemical entities, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780030528.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07809708 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2654964 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009516557 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007261399 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007809708 Country of ref document: EP Ref document number: 1020097001251 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2007261399 Country of ref document: AU Date of ref document: 20070620 Kind code of ref document: A |